Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
about
Prevention and treatment of cancer targeting chronic inflammation: research progress, potential agents, clinical studies and mechanisms.Metformin and lung cancer risk in patients with type 2 diabetes mellitus.Sitagliptin and oral cancer risk in type 2 diabetes patients.Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors.Changes in glucose metabolism after distal pancreatectomy: a nationwide database study.
P2860
Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
@en
Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
@nl
type
label
Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
@en
Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
@nl
prefLabel
Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
@en
Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
@nl
P2860
P356
P1433
P1476
Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
@en
P2093
Chin-Hsiao Tseng
P2860
P304
18802-18810
P356
10.18632/ONCOTARGET.13390
P407
P577
2016-11-16T00:00:00Z